亚阈值微脉冲黄色激光联合依普利酮药物治疗慢性中心性浆液性脉络膜视网膜病变患者的对比研究。
Subthreshold Micro-Pulse Yellow Laser and Eplerenone Drug Therapy in Chronic Central Serous Chorio-Retinopathy Patients: A Comparative Study.
机构信息
Department of Vitreo-retina, Aravind Eye Hospital , Madurai, India.
出版信息
Semin Ophthalmol. 2020 May 18;35(4):237-245. doi: 10.1080/08820538.2020.1809682. Epub 2020 Aug 27.
PURPOSE
To study the outcomes of subthreshold micropulse yellow laser (SML) and eplerenone (EP) therapy in central serous chorio-retinopathy (cCSCR).
METHODS
Retrospective study of 28 eyes of 27 patients undergoing SML and 20 eyes of 19 patients undergoing EP therapy.
RESULTS
Median duration of follow-up was 8 months for SML and 4.5 months for EP group. Complete SRF resolution was seen in 12/28 (42.8%) eyes in SML and 4/20 (20%) in EP group. Six eyes in SML group and two eyes in EP group needed additional SML. No EP patients demonstrated hyperkalemia warranting stopping of therapy. Baseline visual acuity (VA) was correlated positively with final VA in both groups. Presence/absence of focal leaks had differing outcomes in both treatment groups in terms of anatomical resolution.
CONCLUSION
Both treatment modalities were effective in the management of cCSCR showing comparable favorable anatomical outcomes, but visual outcomes were not significant, probably due to chronicity of the pathology.
目的
研究亚阈值微脉冲黄光激光（SML）和依普利酮（EP）治疗中心性浆液性脉络膜视网膜病变（cCSCR）的结果。
方法
回顾性研究 27 例 28 眼接受 SML 治疗和 19 例 20 眼接受 EP 治疗的患者。
结果
SML 组的中位随访时间为 8 个月，EP 组为 4.5 个月。SML 组中 12/28（42.8%）只眼完全消退 SRF，EP 组中 4/20（20%）只眼完全消退 SRF。SML 组中有 6 只眼和 EP 组中有 2 只眼需要额外的 SML。没有 EP 患者因需要停止治疗而出现高钾血症。两组的基线视力（VA）均与最终 VA 呈正相关。在两组中，存在/不存在局灶性渗漏在解剖学结果方面有不同的影响。
结论
两种治疗方法均能有效治疗 cCSCR，显示出类似的良好的解剖学结果，但视觉结果并不显著，可能是由于该疾病的慢性病程所致。
Zotero 插件